Meiji Holdings Co., Ltd. (President and Representative Director: Naotada Sato; “Meiji Holdings”) hereby notifies that Meiji Seika Pharma Co., Ltd. (President and Representative Director: Masahiko Matsuo; “Meiji Seika Pharma”), one of its operating companies, has reached an agreement on a long-term strategic collaboration partnership on biosimilars with Dong-A Pharmaceutical Co., Ltd. (Headquarters: Seoul, South Korea, CEO: Won-Bae Kim; “Dong-A Pharmaceutical”).

Under this agreement, both companies will collaborate on the research, development, manufacturing and sales of biosimilars. Meiji Seika Pharma and Dong-A Pharmaceutical will obtain marketing authorization of the jointly-developed biosimilar products in Japan and South Korea, respectively and will commercialize those biosimilar products in their respective markets. The companies will conduct joint research on biosimilar products to expand their product portfolios while reducing production costs, and undertaking global clinical trials to advance development. They will also establish a joint venture company (the “JVC”) in Seoul, South Korea, with plans to build a cGMP-compliant biopharmaceutical plant in the Songdo region of the Incheon Free Economic Zone, using both companies’ capital. The goal is for the JVC to work on the production of biosimilars, and obtain marketing authorization of biosimilars throughout the world (excluding Japan and South Korea).

The companies have commenced joint research and development of a Trastuzumab biosimilar (DA-3111), which Dong-A Pharmaceutical has been currently developing. DA-3111 is an antibody drug used in surgical adjuvant treatment of HER2-overexpressing breast cancer and gastric cancer. Also, both companies will discuss and agree on their subsequent development candidates from those biosimilars currently in the research phase, working to quickly expand and enhance their development pipelines. The new biopharmaceutical plant, to be operated by the JVC as a production base for the biosimilars jointly developed by the companies, will start its operation for the production of DA-3111 for development and commercial use.

This strategic collaboration partnership with Dong-A Pharmaceutical is expected to enable them to share both companies’ biopharmaceutical technologies, actively utilize their mutual strengths, boost their competitiveness, and globally expand their biosimilars businesses.

Meiji Seika Pharma is developing its speciality drugs business and generic drugs business, with a focus on the infectious disease and central nervous system disorders. This agreement positions biosimilars as one of its important growth strategies. Through establishment of a long-term partnership with Dong-A Pharmaceutical, Meiji Seika Pharma intends to enter into the biosimilars market, where growth is expected, and reinforce its generic drugs business.

The impact of this agreement on consolidated financial forecasts for fiscal year ending March 31, 2012 is minimal.
Biosimilars
Pharmaceuticals that are equivalent to and have qualities similar to pharmaceuticals applying biotechnology with expired patents, which are developed by manufacturing and sales companies other than the patent holder. Since pharmaceuticals applying biotechnology are generally expensive, the introduction of biosimilar products will be well received by the public because of the reduced financial burden on patients.

Meiji Seika Pharma Co., Ltd.
Meiji Holdings Co., Ltd., the parent company of Meiji Seika Pharma, reorganized its operating companies, which resulted in the establishment of Meiji Seika Pharma on April 1, 2011. Meiji Seika Pharma, which inherited the pharmaceuticals business of Meiji Seika Kaisha, Ltd., is a “Speciality and Generic Pharmaceuticals Company” with a focus on the infectious disease field, the central nervous system disorders field, and the generic drugs business.
For details on Meiji Seika Pharma, see http://www.meiji-seika-pharma.co.jp/english/index.html.

Dong-A Pharmaceutical Co., Ltd.
South Korea’s largest pharmaceuticals manufacturer, established in 1932. Its products span a wide range, including cardiovascular and digestive system disease treatments. Dong-A Pharmaceutical is also working on the research, development and commercialization of pharmaceuticals that apply biotechnology, including several biosimilars. It already manufactures and sells biotechnology-based pharmaceuticals such as Somatropin in South Korea. For details on Dong-A Pharmaceutical, see http://www.donga.co.kr.